BEYFORTUS (Sanofi-Aventis Australia Pty Ltd)
Product name
BEYFORTUS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
nirsevimab
Registration type
NCE/NBE
Indication
BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:
- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
BEYFORTUS should be used in accordance with official recommendations.
This webpage on the TGA website was printed on 10 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/resources/prescription-medicines-registrations/beyfortus-sanofi-aventis-australia-pty-ltd